These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38007154)
1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study). Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S Gastroenterol Hepatol; 2024 Oct; 47(8):821-833. PubMed ID: 38007154 [TBL] [Abstract][Full Text] [Related]
2. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study). Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S Gastroenterol Hepatol; 2024; 47(7):750-758. PubMed ID: 38219960 [TBL] [Abstract][Full Text] [Related]
3. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease. Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection. Hoyois A; Gulkilik C; Mekkaoui L; Dahma H; Wambacq V; Minsart C; Rosewick N; Liefferinckx C; Amininejad L; Van Gossum A; Cremer A; Vandenberg O; Franchimont D Acta Gastroenterol Belg; 2024; 87(2):263-273. PubMed ID: 39210758 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954 [TBL] [Abstract][Full Text] [Related]
6. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T; Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149 [TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919 [TBL] [Abstract][Full Text] [Related]
8. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection? Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059 [TBL] [Abstract][Full Text] [Related]
9. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV. Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206 [TBL] [Abstract][Full Text] [Related]
11. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC Front Immunol; 2022; 13():920333. PubMed ID: 35865529 [TBL] [Abstract][Full Text] [Related]
13. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U Front Immunol; 2022; 13():889138. PubMed ID: 35634285 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
16. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease. Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819 [TBL] [Abstract][Full Text] [Related]
17. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R; Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789 [TBL] [Abstract][Full Text] [Related]
18. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose. Roozen GVT; Prins MLM; Prins C; Janse JJ; de Gruyter HLM; Pothast CR; Huisman W; Koopman JPR; Lamers OAC; Kuijer M; Myeni SK; van Binnendijk RS; Hartog GD; Heemskerk MHM; Jochems SP; Feltkamp MCW; Kikkert M; Rosendaal FR; Roestenberg M; Visser LG; Roukens AHE Clin Microbiol Infect; 2024 Jul; 30(7):930-936. PubMed ID: 38552793 [TBL] [Abstract][Full Text] [Related]
19. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. Dai C; Dong ZY; Wang YN; Huang YH; Jiang M Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up. Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]